Yash Soni presented a Bi-Institutional Safety Analysis of Combining Radiotherapy and Enfortumab Vedotin in Advanced Urothelial Cancer. The landscape of advanced urothelial carcinoma ... and RT ...

The FDA has started a priority review of Seattle Genetics and Astellas’ antibody-drug conjugate enfortumab vedotin ... advanced urothelial carcinoma (UC) – the most common form of bladder ...

Long-Term Outcomes in EV-301, Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Advanced ... He presents findings on the treatment's safety profile, potential adverse effects, ...

Enfortumab vedotin plus pembrolizumab was previously granted a priority review designation from the MHLW.

Follow-up with cholesterol control and audiological assessments is suggested for cisplatin-treated patients with cancer. Srigowri Kota, MSN, BA, APRN, AGNP-C, AOCNP, provides an in-depth look at ...

Enfortumab vedotin plus pembrolizumab was previously granted a priority review designation from the MHLW. Japan’s Ministry of Health, Labour, and Welfare (MHLW) has approved the combination of ...

Japan’s MHLF approves Padcev with Keytruda for first-line treatment of radically unresectable urothelial carcinoma: Tokyo Wednesday, September 25, 2024, 11:00 Hrs [IST] Astellas ...

Aragon-Ching, discussed recent updates from the JAVELIN Bladder 100 trial. She also discussed ongoing research ... further discussed the background and results of the EV-103 study in patients with ...

Enfortumab vedotin showed a robust disease control rate in patients with urothelial cancer outside of a clinical ... control rate in patients with advanced urothelial carcinoma (aUC) outside ...

In the last decade, immunotherapy with PD-1/PD-L1 inhibitors has transformed the treatment of relapsed urothelial carcinoma (UC), the most common form of bladder cancer. Now, new data suggests new ...

Non-muscle-invasive bladder cancer (NMIBC) is a type of bladder cancer where the tumor remains confined to the bladder's ...